Thomas Gianis, MD
Urology · Summit, NJNPI 1376587501
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $857 of the $1,380 with a category attached, or 62.1%. Philips North America LLC accounts for 64.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,018, more than ten times the $54 reported in 2019. That places this record below the midpoint for urology clinicians in NJ, where the typical reported total is $2,095.
Across 13 payments — averaging $106.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$896
- Boston Scientific$220
- Urogen Pharma, Inc.$146
- Astellas Pharma US Inc$54
- AstraZeneca$35
- Ferring Pharmaceuticals Inc.$16
- plus $14 from 1 others
What the payments were for
- Travel & lodging$85762%
- Food & beverage$48835%
- Education$353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 5 | $896 |
| Boston Scientific | 3 | $220 |
| Urogen Pharma, Inc. | 1 | $146 |
| Astellas Pharma US Inc | 1 | $54 |
| AstraZeneca | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$639
- PHOENIX$218
- JELMYTO$146
- SpaceOAR System$118
How this compares
$1,380 in reported general payments places this provider in the 35th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 12 | $1,458 |
| Tamsulosin Hcl | 104 | $1,365 |
| Finasteride | 66 | $1,231 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 42 | $1,075 |
| Silodosin | 16 | $958 |
| Ciprofloxacin Hcl | 47 | $284 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Other urology in Summit
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.